ArticleMolecular biology reports2026
Perillaldehyde reduces mitochondrial oxidative stress damage by regulating KCNT2/NR1D1 protein activity in vascular dementia rats.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study explores the therapeutic potential of perillaldehyde (PAE) in a rat model of vascular dementia (VD), focusing on its effects on cognitive function, neuronal morphology, cell proliferation, apoptosis, oxidative stress, and mitochondrial function. METHODS AND
resultsThirty-two male Sprague-Dawley rats were divided into four groups: control, PAE treatment, VD model, and VD + PAE combined. Morris water maze results showed that PAE improved spatial learning and memory, reducing escape latency by 46.2% and increasing target quadrant time by 58.7%. HE and Golgi staining indicated increased dendrite length and spine density by 39.5% and 42.1%. Immunohistochemistry showed a 2.3-fold increase in neuronal proliferation, and TUNEL staining revealed a 55% reduction in apoptosis. PAE also reduced oxidative stress, lowering NOX2/NOX4 expression by 45%, decreasing MDA by 37%, and increasing SOD and GSH by 52% and 48%, respectively. Mitochondrial function was improved, with enhanced membrane potential and reduced Drp1 and FIS1 expression. At the molecular level, PAE upregulated KCNT2 and NR1D1 proteins and inhibited PI3K and JNK pathways.
conclusionsIn conclusion, PAE alleviates mitochondrial oxidative stress and neuronal damage via the KCNT2/NR1D1 pathway, showing promise for treating vascular dementia.
Indexed as
Identifiers
41931178What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.